Medicare will move ostomy supplies to eight national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.
|Articles|December 30, 2020
The Top 5 News and Updates in Follicular Lymphoma That Patients May Have Missed in 2020
Author(s)CURE staff
A roundup of some of the most read news and updates in follicular lymphoma in 2020 from CURE®.
Advertisement
There have been several updates in the field of follicular lymphoma in 2020. Here, CURE® looks back at some of the top news and updates in this field that patients read the most.
- In addition to showing clinically meaningful, durable responses, Tazverik (tazemetostat) was generally well-tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to the results of an open-label, single-arm, multicenter phase 2 study.
READ MORE .
- Results of an interim analysis of a phase 2 trial demonstrated that patients with relapsed or refractory follicular lymphoma treated with Kymriah (tisagenlecleucel) – a CAR-T cell therapy – achieved a targeted complete response rate.
READ MORE . - “Collectively, our mature data provide the most definitive evidence supporting current guidelines, that HDT/ASCT should not be offered to unselected patient(s) (with follicular lymphoma) in the frontline setting,” the authors of a study published in Blood Advances wrote.
READ MORE . - A study evaluating the efficacy of Aliqopa (copanlisib) in combination with Rituxan (rituximab) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after at least one prior line of therapy also involving Rituxan has met its primary endpoint, according to Aliqopa’s manufacturer, Bayer.
READ MORE . - During CURE®’s Educated Patient® Leukemia and Lymphoma Summit, an expert from the Georgia Cancer Center discussed how one recently approved drug and two experimental treatments offer the promise of a wider range of options for patients with follicular lymphoma.
READ MORE .
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
The National Comprehensive Cancer Network released its first patient guideline written for caregivers on Oct. 27, 2026. The free guide covers emotional support, money, legal questions, medical tasks and caregivers' own well-being.
Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
A national survey study of about 200,000 adults, published in Supportive Care in Cancer, found that people caring for someone with cancer had 89% higher odds of frequent mental distress than people who were not caregivers.
Advertisement
Advertisement
Trending on CURE
1
Medicare to Cut Ostomy Suppliers to 8 Contracts: What Patients Need to Know
2
3 ESMO 2026 Results in Endometrial and Breast Cancer to Know
3
3 Quality-of-Life Results From ESMO 2026 Patients Should Know
4
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
5